Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality.
Eur Cytokine Netw
; 31(3): 81-93, 2020 Sep 01.
Article
em En
| MEDLINE
| ID: mdl-33361013
ABSTRACT
Coronavirus disease (COVID-19) reached pandemic proportions at the beginning of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory distress syndrome are the leading causes of death in severely or critically ill patients. The elevated cytokine levels in severe patients in comparison with mildly affected patients suggest that cytokine release syndrome (CRS) occurs in the severe form of the disease. In this paper, the significant role of pro-inflammatory cytokines, including IL-1, IL-6, and TNF-alpha, and their mechanism of action in the CRS cascade is explained. Potential therapeutic approaches involving anti-IL-6 and anti-TNF-alpha antibodies to fight COVID-19 and reduce mortality rate in severe cases are also discussed.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Interleucina-6
/
Fator de Necrose Tumoral alfa
/
Pandemias
/
Síndrome da Liberação de Citocina
/
SARS-CoV-2
/
COVID-19
/
Tratamento Farmacológico da COVID-19
/
Anticorpos
Tipo de estudo:
Etiology_studies
Limite:
Humans
Idioma:
En
Revista:
Eur Cytokine Netw
Assunto da revista:
ALERGIA E IMUNOLOGIA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Irã